Director's Dealing • Mar 3, 2025
Director's Dealing
Open in ViewerOpens in native device viewer
In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation) and commission delegated regulation (EU) 1052/2016 of 8 March 2016, Novonesis reports the following transactions under ISIN DK0060336014, Novonesis (Novozymes) B shares under the symbol NSIS B.
Initial notification
a) Position/status Executive Vice President, Strategy & Integration
a) Name Henrik Jørck Nielsen
2. Reason for the notification
March 5, 2025 Company announcement No. 05
Contact information Investor relations
Tobias Bjorklund +45 3077 8682 [email protected]
Anders Enevoldsen +45 5350 1453 [email protected]
Katrine Spedtsberg Poulsen [email protected]
Novonesis is a global leading biosolutions company transforming the way we all produce, consume and live. In more than 30 industries our biosolutions are helping companies meet their business needs and the needs of our planet. Our 10,000 people worldwide work closely with our partners and customers to challenge conventional thinking and transform business with biology.
Novozymes A/S, part of Novonesis Group Krogshoejvej 36

Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.